Table 2 Post-vaccination adverse events (AE)
Post-vaccination adverse events (AEs) | AE after first dose n = 36(%) | AE after second dose n = 36(%) | Total n = 72 doses (%) | 95% CI |
|---|---|---|---|---|
Local AEs (at least one AE) | 24 (66.7%) | 24 (66.7%) | 48 (66.7%) | 55.3–76.7 |
Pain at site of injection | 22 (61.1%) | 23 (63.9%) | 45 (62.5%) | 51.0–73.0 |
Swelling | 8 (22.2%) | 9 (25.0%) | 17 (23.6%) | 15.0–34.3 |
Erythema | 9 (25.0%) | 8 (22.2%) | 17 (23.6%) | 15.0–34.3 |
Ipsilateral painful LNs | 0 (0.0%) | 1 (2.8%) | 1 (1.4%) | 0.2–6.3 |
Systemic AEs (at least one AE) | 22 (61.1%) | 25 (69.4%) | 47 (65.3%) | 53.9–75.5 |
Fever | 9 (25.0%) | 16 (44.4%) | 25 (34.7%) | 24.5–46.1 |
Chills | 4 (11.1%) | 9 (25.0%) | 13 (18.1%) | 10.5–28.1 |
Headache | 16 (44.4%) | 14 (38.9%) | 30 (41.7%) | 30.8–53.2 |
Diarrhea | 0 (0.0%) | 0 (0.0%) | 0 (0%) | 0–5 |
Nausea | 7 (19.4%) | 7 (19.4%) | 14 (19.4%) | 11.6–29.7 |
Myalgia | 15 (41.7%) | 17 (47.2%) | 32(44.4%) | 33.4–56.0 |
Tiredness | 15 (41.7%) | 20 (55.6%) | 35 (48.6%) | 37.3–60.0 |
New transient joint pain | 3 (8.3%) | 6 (16.7%) | 9 (12.5%) | 6.4–21.6 |
Allergy | 1 (2.8%) | 4 (11.1%) | 5 (6.9%) | 2.7–14.6 |
Subjective flaring of 1ry disease | 1 (2.8%) | 0 (0.0%) | 1 (1.4%) | 0.2–6.3 |
Chest pain | 2 (5.6%) | 3 (8.3%) | 5 (6.9%) | 2.7–14.6 |
Serious AE | 0 (0.0%) | 0(0.0%) | 0 (0%) | 0–5 |
Adverse events | 29 (80.6%) | 31 (86.1%) | 83.3 | 73.5–90.6 |